Obesity With Diabetes

Metabolic Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Kailera Therapeutics
Kailera TherapeuticsCA - San Diego
1 program
1
KAI-9531Phase 31 trial
Active Trials
NCT07284901Recruiting1,700Est. Apr 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
Kailera TherapeuticsKAI-9531

Clinical Trials (1)

Total enrollment: 1,700 patients across 1 trials

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Start: Jan 2026Est. completion: Apr 20281,700 patients
Phase 3Recruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,700 patients
1 companies competing in this space